The news: OpenAI is betting that its lower-cost ad tier, ChatGPT Go, will become a dominant revenue driver. It expects the $8 per month offering will attract new users this year and encourage existing paid subscribers to downgrade, per The Information.
The company predicted at the start of 2026 that ChatGPT Go would grow 36-fold to 112 million users this year while its $20 per month ChatGPT Plus tier would fall 80% to 9 million.
This dependence on ChatGPT Go is likely coming from OpenAI’s ambitious prediction that ads will be one of its biggest money makers, generating 36% of its revenues by 2030, per The Information.
Zooming out: The pivot toward an ad-dominated model suggests both ambition and pressure—OpenAI has missed multiple revenue goals so far this year, per The Wall Street Journal, and failed to reach its target of 1 billion users by the end of 2025.
The move to refocus income on ads rather than subscriptions was similarly taken by Netflix, which successfully added a less-expensive, ad-supported tier in 2022 to drive subscriber count and overall revenues.
The battleground: One of ChatGPT’s primary competitors—Anthropic’s Claude—has so far succeeded on an ad-free business model. Claude pulls about 80% of its revenues from enterprise customer subscriptions, per CEO Dario Amodei.
Enterprise customers make up about 40% of OpenAI’s business, per CNBC, leaving it to rely more on consumer-facing offerings. Sacrificing its higher-priced Plus tier to accelerate ChatGPT Go adoption suggests OpenAI sees limited headroom in premium subscriptions on their own.
Implications for the industry: OpenAI’s pivot shows the genAI leader is starting to follow the same path as search and social, where user growth matters more than pricing power and ads drive longer-term revenues.
That evolving strategy could intensify competition around engagement as platforms battle to capture and monetize user attention rather than differentiate on premium features alone.
You've read 0 of 2 free articles this month.
685 Third Avenue21st FloorNew York, NY 100171-800-405-0844
1-800-405-0844[email protected]